Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Still a Buy?

Key Points

• Genmab A/S shares gapped up from a previous close of $311.75 to an opening price of $329.20 and last traded at $335.77 with a trading volume of 24,041 shares.
• The company reported a strong earnings per share of $5.42 for the quarter, surpassing estimates by $1.43, despite earning slightly less revenues than expected at $925 million.
• Genmab A/S has a market cap of $22.18 billion, a PE ratio of 16.86, and a beta of 0.95, indicating stable stock performance.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $311.75, but opened at $329.20. Genmab A/S shares last traded at $335.77, with a volume of 24,041 shares trading hands.

Genmab A/S Stock Performance

The company has a 50 day moving average of $252.50 and a two-hundred day moving average of $220.35. The stock has a market cap of $22.18 billion, a PE ratio of 16.86 and a beta of 0.95.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, beating the consensus estimate of $3.99 by $1.43. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $949.06 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.